Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label, randomized, two-period, two-treatment, cross-over, single dose fed bioequivalence study of Emtricitabine, Tenofovir Alafenamide and Dolutegravir Tablets (200mg/25mg/50mg) versus DESCOVY® tablets (200mg/25mg; Gilead Sciences) and TIVICAY® tablets (50mg; ViiV Healthcare) in healthy adult volunteers

Trial Profile

Open label, randomized, two-period, two-treatment, cross-over, single dose fed bioequivalence study of Emtricitabine, Tenofovir Alafenamide and Dolutegravir Tablets (200mg/25mg/50mg) versus DESCOVY® tablets (200mg/25mg; Gilead Sciences) and TIVICAY® tablets (50mg; ViiV Healthcare) in healthy adult volunteers

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2018

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top